ACE inhibitors, tricyclic antidepressant ---> SmPC of [captopril] of eMC
ACE inhibitors may enhance the hypotensive effects of certain tricyclic antidepressants and antipsychotics. Postural hypotension may occur.
Acebutolol, tricyclic antidepressant
Concomitant administration may increase the blood pressure lowering effect of beta-blockers.
Acetazolamide, tricyclic antidepressant
Acetazolamide, urinary alkalinizing agent, increases the pH of renal tubular urine and decreases the urinary excretion of tricyclic antidepressant
Acetylsalicylic acid, tricyclic antidepressant
Respiratory weakness may occur
Aclidinium/formoterol [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Duaklir Genuair should be administered with caution to patients being treated with medicinal products known to prolong the QTc interval because the action of formoterol on the cardiovascular system may be potentiated
Adrenaline [1], tricyclic antidepressant ---> SmPC of [1] of eMC
The sympathomimetic effect of epinephrine may be potentiated with the simultaneous intake of tricyclic antidepressants and are contraindicated
Adrenaline, tetracyclic antidepressant
The antidepressant may enhance the cardiovascular effects of sympathomimetic agent resulting in severe arrhytmias, tachycardia, hypertension and hyperpyrexia
Alcohol, antidepressants
Alcohol intake is not advisable during antidepressant treatment
Alcohol, tetracyclic antidepressant [2] ---> SmPC of [2] of eMC
Alcohol intake is not advisable during antidepressant treatment
Alcohol, tricyclic antidepressant ---> SmPC of [imipramine] of eMC
Tricyclic antidepressants may potentiate the CNS depressant effects of alcohol
Alizapride, sedative antidepressants
Increased CNS depressant effect
Alprazolam [1], antidepressants ---> SmPC of [1] of eMC
Enhancement of the central depressive effect may occur in case of concomitant use of alprazolam with other CNS depressants
Alprazolam, tetracyclic antidepressant
The co-administration may increase the plasma levels of antidepressant
Alprazolam, tricyclic antidepressant
The co-administration may increase the plasma levels of antidepressant
Amantadine, tricyclic antidepressant
The co-administration of amantadine with drugs that prolong the QT interval is contraindicated
Amezinium, tricyclic antidepressant
Enhancement of sympathomimetic effect
Amfepramone, antidepressants
The indirect sympathomimetic effect of amfepramone may be dangerously enhanced by antidepressants
Amifampridine [1], tricyclic antidepressant ---> SmPC of [1] of EMA
The concomitant use of amifampridine and substances known to lower the epileptic threshold leads to an increased risk of seizures
Amiloride/hydrochlorothiazide, tricyclic antidepressant
The hypotensive effect of amiloride/hydrochlorothiazide can be enhanced by tricyclic antidepressants
Amiodarone, tricyclic antidepressant
The use of amiodarone with other antiarrhythmics or arrhytmogenic medicinal products may increase the incidence of cardiac arrhythmias and should be avoided
Amisulpride, tricyclic antidepressant
Concomitant use of amisulpride with tricyclic antidepressants is not recommended
Amitriptyline, antidepressants
Increased adverse effects. The concomitant use should be done with caution
Amlodipine/valsartan [1], tricyclic antidepressant ---> SmPC of [1] of EMA
The combination may increase the antihypertensive effect
Ammonium chloride, tricyclic antidepressant
Possible decrease of tricyclic antidepressant effect
Amprenavir [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Careful monitoring of the therapeutic and adverse reactions of tricyclic antidepressants is recommended when they are concomitantly administered with amprenavir
Anaesthetics, tricyclic antidepressant
The co-administration may cause a mutual potentiation of the depressor effect on the CNS. Anaesthetics given during tricyclic antidepressant therapy may increase the risk of arrhythmias and hypotension
Antiadrenergics, tricyclic antidepressant
The tricyclic antidepressant may diminish or abolish the antihypertensive effects of adrenergic blocker
Antiarrhythmics, tricyclic antidepressant ---> SmPC of [clomipramine] of eMC
Tricyclic antidepressants should not be employed in combination with antiarrhythmic agents that are strong CYP2D6 inhibitors
Anticholinergics, tetracyclic antidepressant
Tetracyclic antidepressant may potentiate the effects of medicinal products with anticholinergic properties on the eye, central nervous system, bowel and bladder
Anticholinergics, tricyclic antidepressant ---> SmPC of [imipramine] of eMC
Tricyclic antidepressants may potentiate the effects of anticholinergic agents on the eye, central nervous system, bowel and bladder.
Antidepressants with serotonergic effect, tricyclic antidepressant ---> SmPC of [vortioxetine] of EMA
Caution is advised when co-administrating medicines capable of lowering the seizure threshold.
Antidepressants [1], flupentixol ---> SmPC of [1] of eMC
In common with other antipsychotics, flupentixol enhances the response to other CNS depressants.
Antidepressants, antihypertensives
Orthostatic hypotension may be aggravated
Antidepressants, benzodiazepines
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Antidepressants, bromazepam
Enhancement of the depressor effect on the central nervous system
Antidepressants, bromelain
Bromelain may increase drowsiness caused by some medicinal products
Antidepressants, brotizolam
The co-administration of brotizolam with other central nervous system depressants may enhance the central nervous depressant effect
Antidepressants, bupropion [2] ---> SmPC of [2] of eMC
There is an increased risk of seizures occurring with the use of bupropion in the presence of predisposing risk factors which lower the seizure threshold.
Antidepressants, carbamazepine
The co-administration may promote the neurological adverse effects.
Antidepressants, cathine
The co-administration may dangerously enhance the indirect sympathomimetic effect of cathine
Antidepressants, celiprolol
Additive effect
Antidepressants, chlordiazepoxide [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur if chlordiazepoxide is combined with other CNS-depressant drugs.
Antidepressants, clobazam [2] ---> SmPC of [2] of eMC
Especially when clobazam is administered at higher doses, an enhancement of the central depressive effect may occur in cases of combination with other central depressive drugs
Antidepressants, clobenzorex
The co-administration is contraindicated
Antidepressants, dantrolene
The co-administration of dantrolene and CNS depressants should be avoided due to the adverse reactions of dantrolene may be enhanced (specially the CNS depressant effect and muscle weakness)
Antidepressants, dapoxetine [2] ---> SmPC of [2] of eMC
Caution is advised if the concomitant administration of dapoxetine and CNS active medicinal products is required
Antidepressants, diazepam [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur
Antidepressants, dipotassium clorazepate
The combination of CNS depressors may mutually potentiate the depressor effect on the CNS
Antidepressants, diuretics ---> SmPC of [amlodipine/valsartan/hydrochlorothiazide] of EMA
The hyponatraemic effect of diuretics may be intensified by concomitant administration of antidepressants. Caution is indicated in long-term administration of these medicinal products.
Antidepressants, doxepin
The co-administration may enhance the central sedative effect
Antidepressants, doxylamine
Antihistaminic agents have additive effects with other CNS depressants
Antidepressants, efavirenz/emtricitabine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA
Atripla is contraindicated with concomitant use of drugs that are known to prolong the QTc interval and could lead to Torsade de Pointes
Antidepressants, flunitrazepam
The co-administration may cause a mutual potentiation of effects
Antidepressants, flurazepam [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Antidepressants, gliquidone
Hypoglycemic reactions may occur as expression of enhancement effect of gliquidone with gliquidone is co-administered with antidepressive.
Antidepressants, IMAOs
The combination should be avoided due to increased risk of hypertension
Antidepressants, levacetylmethadol
The co-administration may increase the risk of overdose and requires close medical monitoring.
Antidepressants, levodopa
Antidepressants can accelerate the metabolism of levodopa
Antidepressants, loprazolam [2] ---> SmPC of [2] of eMC
Combination with CNS depressants causes enhancement of the central depressive effects of loprazolam.
Antidepressants, lorazepam [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur if lorazepam is combined with other CNS depressants
Antidepressants, lormetazepam
The benzodiazepines, including lormetazepam produce additive CNS depressant effects when co-administered with other medications which themselves produce CNS depression
Antidepressants, losartan/hydrochlorothiazide [2] ---> SmPC of [2] of eMC
Potentiation of orthostatic hypotension may occur.
Antidepressants, medazepam
The co-administration of medazepam with other central nervous system depressants may enhance the central nervous depressant effect.
Antidepressants, naltrexone/bupropion [2] ---> SmPC of [2] of EMA
Caution should be used when prescribing naltrexone/bupropion to patients with predisposing factors that may increase the risk of seizure
Antidepressants, neuroleptics
Potentiation may occur if antipsychotic drugs are combined with CNS depressants
Antidepressants, nitrazepam
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Antidepressants, norpseudoephedrine
The co-administration may dangerously enhance the indirect sympathomimetic effect of norpseudoephedrine
Antidepressants, oxazepam
Enhancement of other CNS depressant drugs
Antidepressants, oxycodone [2] ---> SmPC of [2] of eMC
Central nervous system depressants can enhance the adverse reactions of oxycodone, in particular respiratory depression.
Antidepressants, perazine
The effect of perazine on the QT interval is likely to be potentiated by concurrent use of other drugs that also prolong the QT interval. Therefore, concurrent use of these drugs should be avoided
Antidepressants, phenothiazines
Phenothiazine may enhance the effect of other CNS depressants
Antidepressants, pimozide [2] ---> SmPC of [2] of eMC
As with other neuroleptics, pimozide may increase the central nervous system depression produced by other CNS depressant drugs
Antidepressants, prazepam
Concomitant use of prazepam and other CNS depressant drugs can mutually enhance the effects
Antidepressants, promazine
The concomitant administration of promazine with antidepressants may result in potentiation of their effects
Antidepressants, proteolytic enzymes enriched in bromelain [2] ---> SmPC of [2] of EMA
Bromelain may increase drowsiness caused by some medicinal products
Antidepressants, quazepam
The co-administration may cause a mutual potentiation of the depressor effect on the CNS
Antidepressants, reboxetine [2] ---> SmPC of [2] of eMC
Concomitant use of reboxetine with other antidepressants (tricyclics, MAO inhibitors, SSRIs and lithium) has not been evaluated during clinical trials.
Antidepressants, rotigotine [2] ---> SmPC of [2] of EMA
Because of possible additive effects, caution should be advised when patients are taking sedating medicinal products or other CNS (central nervous system) depressants or alcohol in combination with rotigotine.
Antidepressants, sibutramine [2] ---> SmPC of [2] of eMC
Concomitant use, or use during the past 2 weeks, of other centrally-acting drugs for the treatment of psychiatric disorders (such as antidepressants, antipsychotics) or for weight reduction is contraindicated
Antidepressants, sodium oxybate [2] ---> SmPC of [2] of EMA
A possible additive effect of antidepressants and sodium oxybate cannot be excluded. The rate of adverse events has increased when sodium oxybate is co-administered with tricyclic antidepressants.
Antidepressants, sodium valproate [2] ---> SmPC of [2] of eMC
Valproate may potentiate the effect of other psychotropics; therefore, clinical monitoring is advised and the dosage of the other psychotropics should be adjusted when appropriate.
Antidepressants, St. John's wort
The co-administration may increase the serotoninergic effects and the adverse reactions. St. John's Wort should be avoided
Antidepressants, telmisartan [2] ---> SmPC of [2] of EMA
An orthostatic hypotension may be aggravated
Antidepressants, telmisartan/amlodipine [2] ---> SmPC of [2] of EMA
Medicinal products with blood pressure lowering potential may potentiate the hypotensive effects of all antihypertensives
Antidepressants, temazepam
Enhancement of the central depressive effect may occur if temazepam is combined with antidepressants
Antidepressants, thioridazine
Phenothiazine may enhance the effect of other CNS depressants
Antidepressants, tranylcypromine
The effect of CNS depressants can be enhanced by co-administration of tranylcypromine
Antidepressants, triazolam
Increased CNS depressant effect with the co-administration of triazolam and antidepressants may occur
Antidepressants, trifluoperazine [2] ---> SmPC of [2] of eMC
Potentiation may occur if antipsychotic drugs are combined with CNS depressants
Antidepressants, trimipramine
The co-administration may enhance the parasympatholytic effect of trimipramine
Antidepressants, valproic acid [2] ---> SmPC of [2] of eMC
Valproate may potentiate the effect of other psychotropics; therefore, clinical monitoring is advised and the dosage of the other psychotropics should be adjusted when appropriate.
Antidepressants, zaleplon [2] ---> SmPC of [2] of EMA
Combination of zaleplon with other CNS-acting compounds may enhance the central sedation
Antidepressants, zolpidem [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur in case of concomitant use of zolpidem with other central nervous system depressants
Antidepressants, zopiclone [2] ---> SmPC of [2] of eMC
The combination with CNS depressants an enhancement of the central depressive effect may occur.
Antidepressants, zotepine
The co-administration may cause a mutual potentiation of effects
Antiepileptics, tetracyclic antidepressant
The enzymatic induction may decrease the plasma levels of the tetracyclic antidepressant
Antiepileptics, tricyclic antidepressant ---> SmPC of [ethosuximide] of eMC
The anticonvulsant effect of antiepileptic agents may be antagonized by tricyclic antidepressants (convulsive threshold lowered)
Antihistamines, tricyclic antidepressant
Antihistamines potentiate the sedative effects of tricyclic antidepressants
Antihypertensives, tricyclic antidepressant
The co-administration may enhance the risk of orthostatic hypotension
Apraclonidine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Apraclonidine is contraindicated in patients receiving tricyclic antidepressants
Articaine/epinephrine, tricyclic antidepressant
The sympathomimetic effect of epinephrine may be potentiated with the simultaneous intake of tricyclic antidepressants and are contraindicated
Atenolol, tricyclic antidepressant
Concomitant use of atenolol with antihypertensive agents as well as other drugs with blood pressure lowering potential may increase the risk of hypotension.
Atenolol/chlortalidone, tricyclic antidepressant
Enhanced antihypertensive effect
Atenolol/nifedipine, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Concomitant use of atenolol with antihypertensive agents as well as other drugs with blood pressure lowering potential may increase the risk of hypotension.
Atomoxetine, tricyclic antidepressant
There is the potential for an increased risk of QT interval prolongation when atomoxetine is administered with other QT prolonging drugs. There is also a risk of lowering the seizure threshold
Atropine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Combination of atropine with other drugs with anticholinergic activity may increase the risk of atropinic adverse effects (urinary retention, constipation, dry mouth).
Atropine, tetracyclic antidepressant [2] ---> SmPC of [2] of eMC
Combination of atropine with other drugs with anticholinergic activity may increase the risk of atropinic adverse effects (urinary retention, constipation, dry mouth).
Azole antifungals, tricyclic antidepressant
Possible increase of plasma levels and toxicity of tricyclic antidepressant
Baclofen [1], tricyclic antidepressant ---> SmPC of [1] of eMC
The co-administration of baclofen with tricyclic antidepressants can potentiate the effect of baclofen and as a result considerable muscle relaxation may occur.
Bamethane, tetracyclic antidepressant
The combination of sympathomimetics with tri or tetracyclic antidepressants should be avoided. Possible enhancement of sympathomimetic effect
Bamethane, tricyclic antidepressant
The combination of sympathomimetics with tri or tetracyclic antidepressants should be avoided. Possible enhancement of sympathomimetic effect
Barbiturates, tetracyclic antidepressant ---> SmPC of [trazodone] of eMC
The metabolism of antidepressants is accelerated due to hepatic effects by barbiturates
Barbiturates, tricyclic antidepressant ---> SmPC of [trazodone] of eMC
The metabolism of antidepressants is accelerated due to hepatic effects by barbiturates
Beclometasone/formoterol/glycopyrronium [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Concomitant treatment with quinidine, disopyramide, procainamide, antihistamines, monoamine oxidase inhibitors, tricyclic antidepressants and phenothiazines can prolong the QT interval and increase the risk of ventricular arrhythmias.
Bendroflumethiazide, tricyclic antidepressant
There is an increased risk of postural hypotension with tricyclic antidepressants.
Benzodiazepines, tetracyclic antidepressant
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Benzodiazepines, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Enhancement of the central depressive effect may occur if benzodiazepines are combined with centrally-acting drugs
Beta-adrenergic agonists, tricyclic antidepressant
Beta-adrenergic agonists should be used with caution in patients treated with tricyclic antidepressants as the effect of beta-adrenergics may be enhanced
Betablockers, tricyclic antidepressant ---> SmPC of [propranolol] of EMA
Drugs that induce postural hypotension may add their effects to that of beta-blockers.
Betanidine, tricyclic antidepressant
The combination may potentiate the effect of tricyclic antidepressant. The antidepressant may decrease/abolish the central hypotensive effect. Combination should be avoided
Betaxolol, tricyclic antidepressant
The combination may cause strong hypotension
Biperiden, tetracyclic antidepressant
The combination of biperiden with other anticholinergic medicinal products may enhance the central and peripheral adverse reactions
Biperiden, tricyclic antidepressant
Tricyclic antidepressants may potentiate the effects of anticholinergic agents on the eye, central nervous system, bowel and bladder.
Bisoprolol [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant use of bisoprolol with antihypertensive agents as well as with other medicinal products with blood pressure lowering potential may increase the risk of hypotension.
Bornaprine, tetracyclic antidepressant
The co-administration of bornaprine with other anticholinergic drugs may enhance the central and peripheral adverse effects
Bornaprine, tricyclic antidepressant
Risk of severe anticholinergic effects (e.g. paralytic ileus, hyperpyrexia)
Breast-feeding, tricyclic antidepressant
A decision must be made to either discontinue breast-feeding or to discontinue/abstain from therapy
Brimonidine [1], tetracyclic antidepressant ---> SmPC of [1] of EMA
The administration of brimonidine with medicinal products which affect noradrenergic transmission is contraindicated
Brimonidine [1], tricyclic antidepressant ---> SmPC of [1] of EMA
The administration of brimonidine with medicinal products which affect noradrenergic transmission is contraindicated
Brinzolamide/brimonidine [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Brinzolamide/brimonidine is contraindicated in patients on antidepressants which affect noradrenergic transmission. Tricyclic antidepressants may blunt the ocular hypotensive response of brinzolamide/brimonidine
Bromhexine, tricyclic antidepressant
Bronchial secretion inhibitors may antagonize the effects of bromhexine
Bromperidol, tricyclic antidepressant
The co-administration may increase the plasma levels of tricyclic antidepressant and decrease the convulsion threshold (seizures)
Budesonide/formoterol [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Concomitant treatment of formoterol with tricyclic antidepressants can prolong the QTc-interval and increase the risk of ventricular arrhythmias.
Bumetanide, tricyclic antidepressant
Bumetanide may potentiate the effects of antihypertensive drugs.
Butylscopolamine [1], tetracyclic antidepressant ---> SmPC of [1] of eMC
The anticholinergic effect may be intensified by hyoscine butylbromide
Butylscopolamine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
The anticholinergic effect may be intensified by hyoscine butylbromide
Calcium antagonists, tricyclic antidepressant
Possible increase of plasma levels and toxicity of tricyclic antidepressant
Captopril [1], tricyclic antidepressant ---> SmPC of [1] of eMC
ACE inhibitors may enhance the hypotensive effects of certain tricyclic antidepressants and antipsychotics. Postural hypotension may occur.
Carbamazepine, tetracyclic antidepressant
The co-administration may increase the risk of cardiac conduction abnormalities
Carbamazepine, tricyclic antidepressant
The co-administration may increase the risk of cardiac conduction abnormalities
Carteolol, tricyclic antidepressant
Antihypertensive effect and increased risk of orthostatic hypotension (additive effect)
Carvedilol [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Carvedilol may potentiate the effects of medicines with antihypertensive adverse reactions such as tricyclic antidepressants
Celiprolol [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant use may potentiate the orthostatic hypotensive effects of beta blockers.
Centrally-acting antihypertensives, tricyclic antidepressant
The combination may potentiate the effect of tricyclic antidepressant and antidepressant may decrease the central hypotensive effect. The combination should be avoided
Certoparin, tricyclic antidepressant
Decreased effect of tricyclic antidepressant
Chlorpromazine [1], sedative antidepressants ---> SmPC of [1] of eMC
The co-administration may increase the CNS depressant effect
Chlorpromazine [1], tetracyclic antidepressant ---> SmPC of [1] of eMC
There is an increased risk of arrhythmias when chlorpromazine is used concomitant with QT prolonging drugs. The combination is not recommended
Chlorpromazine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
There is an increased risk of arrhythmias when chlorpromazine is used concomitant with QT prolonging drugs. The combination is not recommended
Chlorprothixene, tetracyclic antidepressant
The concurrent use of chlorprothixene and drugs that also prolong the QT interval should be avoided
Chlorprothixene, tricyclic antidepressant
The concurrent use of chlorprothixene and drugs that also prolong the QT interval should be avoided
Chlortalidone, tricyclic antidepressant
The co-administration may increase the antihypertensive effects
Cilazapril [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant use of tricyclic antidepressants with ACE inhibitors may result in further reduction of blood pressure
Cimetidine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Cimetidine, enzymatic inhibitor (CYP2D6 and CYP3A4), increases the plasma levels of antidepressant and enhances or prolongs its effects and adverse effects
Cinnarizine, tricyclic antidepressant
Concurrent use of cinnarizine and tricyclic antidepressants may potentiate the sedative effects
Ciprofloxacin, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Ciprofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong QT interval
Cisapride, tetracyclic antidepressant
The co-administration of cisapride with drugs that may prolong the QT interval and/or induce torsades de pointes is contraindicated
Cisapride, tricyclic antidepressant
The co-administration of cisapride with drugs that may prolong the QT interval and/or induce torsades de pointes is contraindicated
Citalopram [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Co-administration of citalopram with medicinal products that prolong the QT interval is contraindicated
Clarithromycin, tricyclic antidepressant
The co-administration may influence the therapeutic effect of both active principles. It may also increase the probability of experiencing side effects.
Class IA antiarrhythmic agents, tricyclic antidepressant ---> SmPC of [imipramine] of eMC
Tricyclic antidepressants should not be employed in combination with anti-arrhythmic agents of the quinidine type.
Clemastine, tricyclic antidepressant
Antihistamines potentiate the sedative effects of tricyclic antidepressants
Clenbuterol, tricyclic antidepressant
The co-administration may enhance the effect of clenbuterol.
Clomipramine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Serotonin Syndrome can possibly occur when clomipramine is administered with other serotonergic co-medications
Clonidine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Orthostatic hypotension may be provoked or aggravated by concomitant administration of clonidine and tricyclic antidepressants
Clopamide, tricyclic antidepressant
Increased hypotensive effect
Cloperastine, tricyclic antidepressant
Antihistaminics enhance the anticholinergic effect
CNS depressants, tetracyclic antidepressant
The antidepressant may potentiate the effects of other central depressant substances
CNS depressants, tricyclic antidepressant ---> SmPC of [clomipramine] of eMC
Tricyclic antidepressants may also potentiate the CNS depressant effects of central depressant drugs
Codeine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Enhanced sedative effect
Contraceptives, tricyclic antidepressant
The oral contraceptive antagonises the antidepressant effect but side-effects may be increased due to increased plasma concentrations of tricyclic.
Coumarin anticoagulants, tricyclic antidepressant ---> SmPC of [imipramine] of eMC
Tricyclic antidepressants may potentiate the anti-coagulant effect of coumarin drugs by inhibiting hepatic metabolism of anticoagulants.
Cyclopentolate, tetracyclic antidepressant [2] ---> SmPC of [2] of eMC
The effects of antimuscarinic agents may be enhanced by the concomitant administration of other drugs with antimuscarinic properties
Cyclopentolate, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
The effects of antimuscarinic agents may be enhanced by the concomitant administration of other drugs with antimuscarinic properties
Cyproheptadine, tricyclic antidepressant
Urinary retention, induction of glaucoma
Dalteparin, tricyclic antidepressant
Dalteparin weakens the tricyclic antidepressant effect (basic medicinal product)
Darifenacin [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Darifenacin is a moderate inhibitor of the enzyme CYP2D6. Caution should be exercised when darifenacin is used concomitantly with medicinal products that are predominantly metabolised by CYP2D6 and which have a narrow therapeutic window
Delapril, tricyclic antidepressant
Concomitant use of tricyclic antidepressants with ACE inhibitors may result in further reduction of blood pressure
Desflurane, tricyclic antidepressant
Desflurane may potentiate the hypotensive effect when is administered with other antihypertensive drugs
Desloratadine/pseudoephedrine [1], tricyclic antidepressant ---> SmPC of [1] of EMA
The combination may result in critical hypertension reactions
Desmopressin [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Substances which are known to induce SIADH may cause an additive antidiuretic effect leading to an increased risk of water retention and/or hyponatraemia.
Dexchlorpheniramine, tricyclic antidepressant
The combination of dexchlorpheniramine with other CNS depressants may enhance the CNS depressant effect. Additive anticholinergic effects
Dextromethorphan/quinidine [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Given the pharmacodynamic and pharmacokinetic interactions, concomitant use of dextromethorphan/quinidine and tricyclic antidepressants is not recommended due to the elevated risk of serotonin syndrome
Dextropropoxyphene, tricyclic antidepressant
Increase of plasma levels of the tricyclic antidepressant. The co-administration is not recommended
Diamorphine, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
The depressant effects of diamorphine may be exaggerated and prolonged by tricyclic antidepressants
Diazoxide, tricyclic antidepressant
Diazoxide may potentiate the effect of hypotensive drugs, what cause a further hypotension
Digital glycosides, tricyclic antidepressant
Delayed impulse conduction/increased risk of rhythm disorders
Digitoxin, tricyclic antidepressant
The co-administration may increase the digitoxin effect and promote heart rhythm disorders
Digoxin, tricyclic antidepressant
Tricyclic antidepressants may increase the risk of cardiac arrhythmias
Dihydralazine, tricyclic antidepressant
The co-administration may enhance the hypotensive and hypnotic effect
Dihydrocodeine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Opiates potentiate the effects of CNS depressants
Diltiazem, tetracyclic antidepressant
Increased hypotensive effect. Caution is recommended
Diltiazem, tricyclic antidepressant
Increased hypotensive effect. Caution is recommended
Dimenhydrinate, tricyclic antidepressant
The co-administration of dimenhydrinate with other anticholinergic drugs may enhance or prolong the anticholinergic effect
Dimethindene, tricyclic antidepressant
Tricyclic antidepressants associated with antihistaminics may have an additive antimuscarinic effect, which increases the risk of worsening glaucoma or urinary retention.
Diphenhydramine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
As diphenhydramine has some antimuscarinic activity, the effects of anticholinergic drugs may be potentiated therefore medical advice should be sought before taking diphenhydramine with such medicines.
Dipivefrine, tricyclic antidepressant
The pressor response to adrenergic agents and the risk of cardiac arrhythmia may be exacerbated
Disopyramide [1], tetracyclic antidepressant ---> SmPC of [1] of eMC
Concomitant administration of disopyramide with other drugs liable to provoke ventricular arrythmias, especially Torsade de Pointes is contra-indicated
Disopyramide [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant administration of disopyramide with other drugs liable to provoke ventricular arrythmias, especially Torsade de Pointes is contra-indicated
Distigmine, tetracyclic antidepressant
The co-administration may antagonize the muscarinic effects of distigmine
Distigmine, tricyclic antidepressant
The co-administration may antagonize the muscarinic effects of distigmine
Disulfiram, tricyclic antidepressant
The intensity of the disulfiram-alcohol reaction may be increased
Diuretics, tricyclic antidepressant ---> SmPC of [imipramine] of eMC
Concurrent use of a tricyclic antidepressant and a diuretic may increase the risk of postural hypotension.
Dofetilide [1], tricyclic antidepressant ---> SmPC of [1] of EMA
The co-administration of dofetilide with drugs known to prolong the QT interval is contraindicated
Dopamine agonists, tricyclic antidepressant
CNS toxicity may be enhanced when tricyclic antidepressants are used in conjunction with dopaminergic.
Dopamine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Tricyclic antidepressants may potentiate the pressor response to dopamine.
Dopaminergic drugs, tricyclic antidepressant
CNS toxicity may be enhanced when tricyclic antidepressants are used in conjunction with dopaminergic.
Doubutamine, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Hypertension and an increased risk of arrhythmias may occur if sympathomimetic agents are given to patients receiving tricyclic antidepressants.
Doxepin, tetracyclic antidepressant
The co-administration may enhance the anticholinergic effect
Doxepin, tricyclic antidepressant
The co-administration may enhance the anticholinergic effect
Doxylamine, tricyclic antidepressant
The combination of doxylamine with other anticholinergic medicinal products may enhance the anticholinergic effects
Dronedarone [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Medicinal products inducing torsades de pointes are contraindicated because of the potential risk of proarrhythmias
Droperidol, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Medicinal products known to prolong the QTc interval should not be concomitantly administered with droperidol.
Duloxetine [1], tricyclic antidepressant ---> SmPC of [1] of EMA
In rare cases, serotonin syndrome has been reported in patients using SSRIs/SNRIs concomitantly with serotonergic agents. Caution is advisable if duloxetine is used concomitantly with serotonergic agents
Eliglustat [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Concomitant administration of eliglustat with CYP2D6 substrates may increase the exposition of these substrates. Lower doses of medicinal products that are CYP2D6 substrates may be required.
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Concentrations of antidepressant agents may be increased when co-administered with cobicistat. Careful dose titration of the antidepressant and monitoring for antidepressant response is recommended.
Enalapril [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant use of tricyclic antidepressants with ACE inhibitors may result in further reduction of blood pressure
Enalapril/hydrochlorothiazide [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant use of tricyclic antidepressants with ACE inhibitors may result in further reduction of blood pressure
Enoxaparin, tricyclic antidepressant
Enoxaparin binds the basic medicinal product and decreases its effects
Entacapone [1], tricyclic antidepressant ---> SmPC of [1] of EMA
The combination should be done with care, because there is currently not enough experience
Ephedrine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Tricyclic antidepressants with ephedrine: Paroxysmal hypertension with possibility of arrhythmias (inhibition of adrenaline or noradrenaline entry in sympathetic fibers).
Ephedrine, tetracyclic antidepressant
The antidepressant may enhance the cardiovascular effects of sympathomimetic agent resulting in severe arrhytmias, tachycardia, hypertension and hyperpyrexia
Epinephrine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
The effects of adrenaline may be potentiated by tricyclic antidepressants.
Eplerenone [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Co-administration of eplerenone with tricyclic anti-depressants may potentially increase antihypertensive effects and risk of postural hypotension.
Erythromycin, tetracyclic antidepressant
Caution is advised with medicinal products that prolong the QT interval
Erythromycin, tricyclic antidepressant
Caution is advised with medicinal products that prolong the QT interval
Escitalopram [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Co-administration of escitalopram with medicinal products that prolong the QT-interval is contraindicated.
Esmolol [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant administration of esmolol and tricyclic antidepressants may increase the blood pressure lowering effect.
Estramustine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Oestrogens have been reported to increase both therapeutic activity and toxicity of tricyclic antidepressants, probably via inhibition of their metabolism.
Estrogens, tricyclic antidepressant ---> SmPC of [estramustine] of eMC
Oestrogens have been reported to increase both therapeutic activity and toxicity of tricyclic antidepressants, probably via inhibition of their metabolism.
Ethchlorvynol, tricyclic antidepressant
The co-administration may cause delirium
Ethosuximide, tricyclic antidepressant
The anticonvulsant effect of antiepileptic agents may be antagonized by tricyclic antidepressants (convulsive threshold lowered)
Etilefrine, tricyclic antidepressant
The co-administration may increase the effect of etilefrine
Felodipine, tricyclic antidepressant
Enhancement of the hypotensive effect of felodipine
Fenfluramine [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Pharmacodynamic interactions with other central nervous system depressants increase the risk of aggravated central nervous system depression.
Fenoterol, tricyclic antidepressant
The co-administration may enhance the effect of adrenergic beta-agonist.
Fesoterodine [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Caution should be exercised in coadministration of fesoterodine with other antimuscarinics and medicinal products with anticholinergic properties as this may lead to more pronounced therapeutic-and side-effects
Flavoxate, tetracyclic antidepressant
Increased anticholinergic effect
Flavoxate, tricyclic antidepressant
Increased anticholinergic effect
Flecainide [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Increased risk of arrhythmias
Fluconazole, tricyclic antidepressant
Possible increase of plasma levels and toxicity of tricyclic antidepressant
Fluoxetine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant therapy of flecainide with drugs predominantly metabolised by CYP2D6, and which have a narrow therapeutic index, should be initiated at or adjusted to the low end of their dose range.
Flupentixol, tricyclic antidepressant
The metabolism of tricyclic antidepressants may be inhibited
Fluphenazine, tricyclic antidepressant
The combination of tricyclic antidepressants with phenothiazines increases the antidepressant levels. It can increase the toxicity of both active principles (anticholinergic effects, decreased seizure threshold, QT prolongation)
Fluspirilene, tricyclic antidepressant
Mutual increase of plasma levels
Formoterol [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Caution should be observed in patients treated with drugs that may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia
Formoterol/glycopyrronium/budesonide [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Concomitant treatment can prolong the QT interval and increase the risk of ventricular arrhythmias.
Fosamprenavir/ritonavir, tricyclic antidepressant ---> SmPC of [fosamprenavir] of EMA
Careful monitoring of the therapeutic and adverse reactions of tricyclic antidepressants is recommended when coadministered with fosamprenavir
Fosinopril [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant use of tricyclic antidepressants with ACE inhibitors may result in further reduction of blood pressure
Furazolidone, tricyclic antidepressant
The co-administration may cause hypertensive crisis. The combination is contraindicated
General anesthetics [1], tricyclic antidepressant ---> SmPC of [1] of eMC
General anaesthetics and local anaesthetics given during tricyclic or tetracyclic anti-depressant therapy may increase the risk of arrhythmias and hypotension, or hypertension.
General anesthetics, tetracyclic antidepressant
General anaesthetics and local anaesthetics given during tricyclic or tetracyclic anti-depressant therapy may increase the risk of arrhythmias and hypotension, or hypertension.
Gestagens, tricyclic antidepressant
Oral contraceptives antagonise the antidepressant effect but side-effects may be increased due to increased plasma concentrations of tricyclics.
Glibenclamide, tricyclic antidepressant
The co-administration may weaken the hypoglycemic effect
Glycerol trinitrate [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Treatment with other agents with hypotensive effects may potentiate the hypotensive effect of glyceryl trinitrate.
Glycerol trinitrate [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Treatment with other agents with hypotensive effects may potentiate the hypotensive effect of glyceryl trinitrate.
Glycopyrronium [1], tricyclic antidepressant ---> SmPC of [1] of EMA
The co-administration of glycopyrronium with other anticholinergic-containing medicinal products has not been studied and is therefore not recommended.
Glycopyrronium/indacaterol/mometasone [1], tricyclic antidepressant ---> SmPC of [1] of EMA
This medicinal product should be administered with caution to patients being treated with tricyclic antidepressants, as any effect of these on the QT interval may be potentiated.
Guanethidine, tricyclic antidepressant
The anti-hypertensive action of guanethidine may be reduced by tricyclic antidepressants
Haloperidol [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Haloperidol is an inhibitor of CYP 2D6. Haldol inhibits the metabolism of tricyclic antidepressants, thereby increasing plasma levels of these drugs.
Histamine dihydrochloride [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Tricyclic anti-depressants may have H1 and H2 receptor blocking properties and should be avoided.
Hydrochlorothiazide, tricyclic antidepressant ---> SmPC of [losartan/hydrochlorothiazide] of eMC
Potentiation of orthostatic hypotension may occur.
Ibutilide, tetracyclic antidepressant
Possible increase of proarrhythmic risk if ibutilide is used with drugs that prolong the QT interval. Contraindicated within 4 hours after completing infusion
Ibutilide, tricyclic antidepressant
Possible increase of proarrhythmic risk if ibutilide is used with drugs that prolong the QT interval. Contraindicated within 4 hours after completing infusion
IMAOs, tricyclic antidepressant ---> SmPC of [safinamide] of EMA
Serious adverse reactions have been reported with the concomitant use of tricyclic antidepressants and MAO inhibitors
Imidapril [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Tricyclic antidepressants, neuroleptics: Increased antihypertensive effect and risk of orthostatic hypotension (additive effect)
Imipramine, tricyclic antidepressant
The co-administration may cause additive effects on the serotonergic system
Indacaterol/mometasone [1], tricyclic antidepressant ---> SmPC of [1] of EMA
This medicinal product should be administered with caution to patients being treated with tricyclic antidepressants, as any effect of these on the QT interval may be potentiated.
Indapamide [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Antihypertensive effect and increased risk of orthostatic hypotension increased (additive effect).
Insulin, tetracyclic antidepressant
Increased hypoglycaemic effect
Insulin, tricyclic antidepressant
Increased hypoglycaemic effect
Iodixanol, tricyclic antidepressant
Medicinal products that reduce the convulsant threshold may cause interactions. It is recommended that these drugs should be discontinued 48 hours before and up to 24 hours after examination
Iohexol, tricyclic antidepressant
Medicinal products that reduce the convulsant threshold may cause interactions. It is recommended that these drugs should be discontinued 48 hours before and up to 24 hours after examination
Iomeprol, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Treatment with drugs that lower the seizure threshold should be discontinued 48 hours before the examination. Treatment should not be resumed until 24 hours post-procedure.
Iopromide, tricyclic antidepressant
Medicinal products that reduce the convulsant threshold may cause interactions. It is recommended that these drugs should be discontinued 48 hours before and up to 24 hours after examination
Iosarcol, tricyclic antidepressant
Medicinal products that reduce the convulsant threshold should be discontinued 48 hours before and up to 24 hours after examination
Iotrolan, tricyclic antidepressant
Medicinal products that reduce the convulsant threshold should be discontinued 48 hours before and up to 24 hours after examination
Isoprenaline, tetracyclic antidepressant
The antidepressant may enhance the cardiovascular effects of sympathomimetic agent resulting in severe arrhytmias, tachycardia, hypertension and hyperpyrexia
Isoprenaline, tricyclic antidepressant
Isoprenaline should not be coadministered with tricyclic antidepressants, due to the combined effect can induce arrythmias
Isosorbide dinitrate [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concurrent intake of drugs with blood pressure lowering properties may potentiate the hypotensive effect
Isosorbide mononitrate, tricyclic antidepressant
The co-administration may potentiate the antihypertensive effect of isosorbide mononitrate and cause a strong anticholinergic effect
Isradipine, tricyclic antidepressant
The co-administration may enhance the hypotensive effect
Labetalol, tricyclic antidepressant
Mutual enhancement of effects. Increased incidence of tremor
Levodopa, tricyclic antidepressant
There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and a levodopa/dopa-decarboxylase inhibitor.
Levodopa, tricyclic antidepressant ---> SmPC of [levodopa/carbidopa/entacapone] of EMA
Rarely, reactions including hypertension and dyskinesia have been reported with the concomitant use of tricyclic antidepressants and levodopa/carbidopa.
Levodopa/carbidopa [1], tricyclic antidepressant ---> SmPC of [1] of EMA
There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the concomitant use of tricyclic antidepressants and levodopa/carbidopa.
Levodopa/carbidopa/entacapone [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Rarely, reactions including hypertension and dyskinesia have been reported with the concomitant use of tricyclic antidepressants and levodopa/carbidopa.
Levofloxacin [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Levofloxacin should be used with caution in patients receiving active substances known to prolong the QT interval
Levomepromazine [1], tetracyclic antidepressant ---> SmPC of [1] of eMC
There is an increased risk of arrhythmias when neuroleptics are used with drugs that prolong the QT interval
Levomepromazine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
There is an increased risk of arrhythmias when neuroleptics are used with drugs that prolong the QT interval
Linezolid [1], tricyclic antidepressant ---> SmPC of [1] of eMC
The co-administration is contraindicated, unless there are facilities available for close observation and monitoring of blood pressure
Lisinopril [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant use of tricyclic antidepressants with ACE inhibitors may result in further reduction of blood pressure
Lithium carbonate, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Increased risk of neurotoxicity. The risk of convulsions may be increased in case of co-administration of lithium with drugs that lower the epileptic threshold
Lithium, tricyclic antidepressant ---> SmPC of [lithium carbonate] of eMC
Increased risk of neurotoxicity. The risk of convulsions may be increased in case of co-administration of lithium with drugs that lower the epileptic threshold
Losartan [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant use of losartan with other substances inducing hypotension may increase the risk of hypotension.
Losartan/hydrochlorothiazide [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant use of losartan with drugs that lower blood pressure, as main or side-effect, may increase the risk of hypotension.
Loxapine [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Caution is advised if loxapine is combined with other medicinal products known to lower the seizure threshold
Mefloquine, tricyclic antidepressant
Concomitant administration of mefloquine and other drugs known to alter cardiac conduction might contribute to a prolongation of the QTc interval.
Mefruside, tricyclic antidepressant
The co-administration may increase the antihypertensive effects
Meglumine and sodium ioxitalamate, tricyclic antidepressant
Medicinal products that reduce the convulsant threshold should be discontinued 48 hours before and up to 24 hours after examination
Melperone, tricyclic antidepressant
The combination of melperone with tricyclic antidepressants may mutually potentiate the effects
Meprobamate, tricyclic antidepressant
Meprobamate may increase the effects of concurrently administered central nervous system depressants.
Meptazinol, tricyclic antidepressant
Possible increased sedation if meptazinol is used with tricyclic antidepressants.
Mequitazine, sedative antidepressants
Central nervous system depressants may enhance the sedative effects of mequitazine
Methadone [1], tricyclic antidepressant ---> SmPC of [1] of eMC
The depressant effects of methadone are likely to be enhanced by depressants of the CNS. As well as CNS depression, there may be respiratory depression and/or hypotension.
Methantheline, tetracyclic antidepressant
Enhancement of anticholinergic effect
Methantheline, tricyclic antidepressant
Enhancement of anticholinergic effect
Methyldopa, tricyclic antidepressant
Concomitant use of methyldopa and antidepressants may enhance the hypotensive effect.
Methylphenidate, tricyclic antidepressant ---> SmPC of [clomipramine] of eMC
Methylphenidate may increase plasma concentrations of tricyclic antidepressants, whose dosage should therefore be reduced.
Metildigoxin, tricyclic antidepressant
Increased risk of cardiac arrhythmias
Metoclopramide, sedative antidepressants
The co-administration may mutually enhance the sedative effects of the CNS. The combination requires caution
Midazolam [1], sedative antidepressants ---> SmPC of [1] of EMA
The co-administration of midazolam with other sedative/hypnotic agents and CNS depressants, including alcohol, is likely to result in enhanced sedation and respiratory depression.
Midodrine, tricyclic antidepressant
The co-administration may cause pronounced hypertension. The combination should be avoided
Mirabegron [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Caution is advised if mirabegron is co-administered with medicinal products with a narrow therapeutic index and significantly metabolised by CYP2D6. Caution is also advised with CYP2D6 substrates that are individually dose titrated.
Moclobemide [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Moclobemide should not be co-administered with 5-HT re-uptake inhibitors (including those which are tricyclic antidepressants) in order to prevent precipitation of serotonergic overactivity
Moexipril, tricyclic antidepressant
Concomitant use of tricyclic antidepressants with ACE inhibitors may result in further reduction of blood pressure
Moxifloxacin [1], tricyclic antidepressant ---> SmPC of [1] of eMC
The co-administration may have an additive effect on the QT interval prolongation. This might lead to an increased risk of ventricular arrhythmias, including torsade de pointes. The combination is contraindicated.
Moxonidine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Tricyclic antidepressants may reduce the effectiveness of centrally acting antihypertensive agents. Moxonidine can potentiate the sedative effect of tricyclic anti-depressants (avoid co-prescribing)
Nadolol, tricyclic antidepressant ---> SmPC of [nebivolol] of eMC
Concomitant use may enhance the hypotensive effect of the beta-blockers (additive effect).
Nadroparin, tricyclic antidepressant
Nadroparin may bind the basic drug and decrease its effect
Nalbuphine, sedative antidepressants
Other central nervous system depressant drugs may increase the risk of respiratory depression, which can be life-threatening in the case of an overdose
Naphazoline, tricyclic antidepressant
The co-administration of naphazoline with tricyclic antidepressants may cause hypertensive crisis
Naratriptan [1], tricyclic antidepressant ---> SmPC of [1] of eMC
There is no evidence of a pharmacokinetic interaction of naratriptan with tricyclic antidepressants
Nebivolol [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant use may enhance the hypotensive effect of the beta-blockers (additive effect).
Neuroleptics, tetracyclic antidepressant
The co-administration with neuroleptics may increase plasma levels of tetracyclic antidepressants
Neuroleptics, tricyclic antidepressant ---> SmPC of [clomipramine] of eMC
Tricyclic antidepressants are known to lower the convulsion threshold and should therefore, be used with extreme caution in patients with concomitant use of neuroleptics or drugs with anticonvulsive properties (e.g. benzodiazepines).
Nicorandil [1], tricyclic antidepressant ---> SmPC of [1] of eMC
If nicorandil is used concomitantly with antihypertensive agents or other medicinal products with blood-pressure-lowering effect the blood-pressure-lowering effect may be increased.
Nicotine, tricyclic antidepressant ---> SmPC of [clomipramine] of eMC
Known inducers of CYP1A2 (e.g. nicotine/components in cigarette smoke), decrease plasma concentrations of tricyclic drugs
Nilvadipine, tricyclic antidepressant
Enhancement of hypotensive effect
Nitroglycerine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Treatment with other agents with hypotensive effects may potentiate the hypotensive effect of glyceryl trinitrate. There is a potential for drugs that cause dry mouth (eg anticholinergic, antimuscarinics, tricyclic antidepressants) to reduce the effectiv
Noradrenaline [1], tricyclic antidepressant ---> SmPC of [1] of eMC
The use of noradrenaline with antidepressants is not recommended because severe, prolonged hypertension and possible arrhythmias may result
Noradrenaline, tetracyclic antidepressant
The use of noradrenaline with antidepressants is not recommended because severe, prolonged hypertension and possible arrhythmias may result
Norephedrine, tetracyclic antidepressant
The antidepressant may enhance the cardiovascular effects of sympathomimetic agent resulting in severe arrhytmias, tachycardia, hypertension and hyperpyrexia
Norephedrine, tricyclic antidepressant
The antidepressant may enhance the cardiovascular effects of sympathomimetic agent resulting in severe arrhytmias, tachycardia, hypertension and hyperpyrexia
Norepinephrine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
The use of noradrenaline with antidepressants is not recommended because severe, prolonged hypertension and possible arrhythmias may result
Norepinephrine, tetracyclic antidepressant
The use of noradrenaline with antidepressants is not recommended because severe, prolonged hypertension and possible arrhythmias may result
Norfenefrine, tricyclic antidepressant
The co-administration may increase the sympathomimetic effect
Norfloxacin [1], tricyclic antidepressant ---> SmPC of [1] of eMC
The fluoroquinolones should be used with caution in patients receiving drugs known to prolong the QT interval
Ofloxacin [1], tricyclic antidepressant ---> SmPC of [1] of eMC
The fluoroquinolones should be used with caution in patients receiving drugs known to prolong the QT interval
Olanzapine [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Olanzapine does not inhibit the main CYP450 isoenzymes in vitro (e.g. 1A2, 2D6, 2C9, 2C19, 3A4). Thus no particular interaction is expected as verified through in vivo studies where no inhibition of metabolism was found
Opicapone [1], tricyclic antidepressant ---> SmPC of [1] of EMA
There is limited experience with opicapone when used concomitantly with tricyclic antidepressants and noradrenaline re-uptake inhibitors. Thus, their concomitant use should be considered with appropriate caution.
Opipramol, tricyclic antidepressant
The co-administration may modify the plasma levels of both active principles
Oral anticoagulants, tricyclic antidepressant
The co-administration may enhance the anticoagulant effect and increase the bleeding risk
Oral contraceptives, tetracyclic antidepressant ---> SmPC of [trazodone] of eMC
The metabolism of antidepressants is accelerated due to hepatic effects by oral contraceptives
Oral contraceptives, tricyclic antidepressant ---> SmPC of [trazodone] of eMC
The metabolism of antidepressants is accelerated due to hepatic effects by oral contraceptives
Orciprenaline, tricyclic antidepressant
Beta-adrenergic agonists should be used with caution in patients treated with tricyclic antidepressants as the effect of beta-adrenergics may be enhanced
Organic nitrates, tricyclic antidepressant ---> SmPC of [nitroglycerine] of eMC
There is a potential for drugs that cause dry mouth (eg anticholinergic, antimuscarinics, tricyclic antidepressants) to reduce the effectiveness of sublingual nitrates.
Orphenadrine, tricyclic antidepressant
Concomitant use of other antimuscarinic drugs can lead to an increase in side effects such as dry mouth and urine retention.
Orthostatic hypotension, tricyclic antidepressant
Potential for inducing orthostatic hypotension
Oxcarbazepine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Patients on tricyclic antidepressant therapy were included in clinical trials and no clinically relevant interactions have been observed.
Oxomemazine, sedative antidepressants
Enhancement of CNS depressant effect
Oxomemazine, tricyclic antidepressant
Enhancement of central anticholinergic effect
Oxprenolol, tricyclic antidepressant
The co-administration may enhance the hypotensive effect
Oxybutynine [1], tricyclic antidepressant ---> SmPC of [1] of EMA
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or medicinal products with anticholinergic activity
Oxymetazoline, tricyclic antidepressant
Increased blood pressure or enhancement of vasoconstrictor effect
Paliperidone [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Potential for inducing orthostatic hypotension. Caution is advised if paliperidone is combined with other medicines known to lower the seizure threshold
Pentaerythritol tetranitrate, tricyclic antidepressant
The co-administration may potentiate the hypotensive effect
Pentamidine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Caution is advised when pentamidine isetionate is concomitantly used with drugs that are known to prolong the QT interval
Pentazocine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Agents with sedative action can enhance the central depressant effects of pentazocine
Perazine, tricyclic antidepressant
The combination of tricyclic antidepressants with phenothiazines increases the antidepressant levels. It can increase the toxicity of both active principles (anticholinergic effects, decreased seizure threshold, QT prolongation)
Perindopril [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant use of tricyclic antidepressants with ACE inhibitors may result in further reduction of blood pressure
Perphenazine, tricyclic antidepressant
Tricyclic antidepressant may potentiate the effects of medicinal products with anticholinergic properties on the eye, central nervous system, bowel and bladder
Pethidine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
The central depressant effects of pethidine may be potentiated by the concurrent use of other CNS depressants; respiratory depression and profound sedation or coma may occur.
Phenelzine, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Phenelzine should not be administered at the same time as, or within 14 days of, treatment with tricyclic antidepressant agents
Phenobarbital [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Tricyclic antidepressants may antagonise the antiepileptic activity of phenobarbital by lowering the convulsive threshold
Phenobarbital, tetracyclic antidepressant
The enzymatic induction may decrease the plasma levels of the tetracyclic antidepressant
Phenothiazines, tricyclic antidepressant
The coadministration may increase the plasma levels of tricyclic antidepressants and/or phenothiazines. It has been reported that the co-administration may result in heart rhythm disorders
Phenprocoumon, tricyclic antidepressant
Enhancement of phenprocoumon effect and increased bleeding risk with the concomitant administration of tricyclic antidepressants
Phenylephrine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
An increased risk of arrhythmias may occur if phenylephrine injection is given to patients receiving tricyclic antidepressants.
Phenylephrine, tetracyclic antidepressant
The antidepressant may enhance the cardiovascular effects of sympathomimetic agent resulting in severe arrhytmias, tachycardia, hypertension and hyperpyrexia
Phenylpropanolamine, tetracyclic antidepressant
The antidepressant may enhance the cardiovascular effects of sympathomimetic agent resulting in severe arrhytmias, tachycardia, hypertension and hyperpyrexia
Phenylpropanolamine, tricyclic antidepressant
The antidepressant may enhance the cardiovascular effects of sympathomimetic agent resulting in severe arrhytmias, tachycardia, hypertension and hyperpyrexia
Phenytoin, tetracyclic antidepressant ---> SmPC of [trazodone] of eMC
The metabolism of antidepressants is accelerated due to hepatic effects by phenytoin
Phenytoin, tricyclic antidepressant ---> SmPC of [trazodone] of eMC
The metabolism of antidepressants is accelerated due to hepatic effects by phenytoin
Pholcodine, tricyclic antidepressant
Pholcodine may enhance the sedative effect of central nervous system depressants
Pimozide [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Concomitant use of pimozide with drugs known to prolong the QT interval is contra-indicated
Pindolol, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Concomitant use of beta-blockers with tricyclic antidepressants may increase the blood pressure lowering effect.
Pindolol/clopamide, tricyclic antidepressant
Concomitant use of pindolol/clopamide and tricyclic antidepressants may increase the blood pressure lowering effect.
Piperidolate, tricyclic antidepressant
The co-administration may increase the risk of adverse effects, e.g. paralytic ileus, retention of urine and blurred vision
Pipotiazine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
The mild anticholinergic effect of neuroleptics may be enhanced by other anticholinergic drugs possibly leading to constipation, heat stroke, etc.
Piretanide, tricyclic antidepressant
The hypotensor effect of piretanide may be potentiated
Pitolisant [1], tetracyclic antidepressant ---> SmPC of [1] of EMA
Tri or tetracyclic antidepressants may impair the efficacy of pitolisant because they display histamine H1-receptor antagonist activity and possibly cancel the effect of endogenous histamine released in brain by the treatment.
Pitolisant [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Tri or tetracyclic antidepressants may impair the efficacy of pitolisant because they display histamine H1-receptor antagonist activity and possibly cancel the effect of endogenous histamine released in brain by the treatment.
Pregnancy, tetracyclic antidepressant
Strict indication
Pregnancy, tricyclic antidepressant
Strict indication
Pridinol, tetracyclic antidepressant
Enhancement of anticholinergic effect
Pridinol, tricyclic antidepressant
Enhancement of anticholinergic effect
Primidone, tricyclic antidepressant
Primidone therapy may lead to altered pharmacokinetics in concomitantly administered drugs, whose metabolism may be increased and lead to lowered plasma levels and/or a shorter half-life.
Procarbazine, tricyclic antidepressant
Procarbazine may enhance the effect of drugs with anticholinergic effects
Procyclidine, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Drugs with anticholinergic properties may increase the anticholinergic action
Promazine, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Concomitant use of promazine with drugs known to prolong the QT interval may increase the risk of ventricular arrhythmias, including torsade de pointes. Therefore, concomitant use of these products is not recommended.
Promethazine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Promethazine will enhance the action of any tricyclic antidepressant
Propafenone [1], tricyclic antidepressant ---> SmPC of [1] of eMC
The effects of propafenone may be potentiated if it is given in combination with agents which depress myocardial activity
Propafenone, tetracyclic antidepressant
The co-administration may enhance the propafenone effect and cause cardiodepressant effects
Propantheline, tricyclic antidepressant
Increased risk of antimuscarinic side effects when antimuscarinics are given with tricyclics or tricyclic-related antidepressants.
Propiverine, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Increased effects of propiverine due to concomitant medication with tricyclic antidepressants (e. g. imipramine)
Propranolol [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Drugs that induce postural hypotension may add their effects to that of beta-blockers.
Propranolol, tetracyclic antidepressant
The co-administration may enhance the antihypertensive effect
Pseudoephedrine [1], tricyclic antidepressant ---> SmPC of [1] of eMC
There may be increased risk of arrhythmias if pseudoephedrine is given to patients receiving tricyclic antidepressants.
Pyridostigmine, tetracyclic antidepressant
The tetracyclic antidepressant antagonizes the muscarinic effects of pyridostigmine
Pyridostigmine, tricyclic antidepressant
The tricyclic antidepressant antagonizes the muscarinic effects of pyridostigmine
QT interval prolonging drugs, tricyclic antidepressant
Combined therapy with drugs which prolong the QT interval is contra-indicated due to the increased risk of torsades de pointes
Quazepam, tetracyclic antidepressant
The co-administration may cause a mutual potentiation of the depressor effect on the CNS
Quazepam, tricyclic antidepressant
The co-administration may cause a mutual potentiation of the depressor effect on the CNS
Quinidine, tricyclic antidepressant ---> SmPC of [clomipramine] of eMC
Tricyclic antidepressants should not be employed in combination with antiarrhythmic agents of the quinidine type.
Quinine, tetracyclic antidepressant
The co-administration of quinine with medicinal products that significant prolong the QT interval is contraindicated
Quinine, tricyclic antidepressant
The co-administration of quinine with medicinal products that significant prolong the QT interval is contraindicated
Quinolones, tricyclic antidepressant ---> SmPC of [norfloxacin] of eMC
The fluoroquinolones should be used with caution in patients receiving drugs known to prolong the QT interval
Ramipril [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Potentiation of the risk of hypotension is to be anticipated. Caution is recommended
Ranolazine [1], tricyclic antidepressant ---> SmPC of [1] of EMA
There is a theoretical risk that concomitant treatment of ranolazine with other drugs known to prolong the QTc interval may give rise to a pharmacodynamic interaction and increase the possible risk of ventricular arrhythmias.
Rasagiline [1], tetracyclic antidepressant ---> SmPC of [1] of EMA
In the post-marketing period, cases of serotonin syndrome associated with agitation, confusion, rigidity, pyrexia and myoclonus have been reported by patients treated with antidepressants/SNRI concomitantly with rasagiline.
Rasagiline [1], tricyclic antidepressant ---> SmPC of [1] of EMA
In the post-marketing period, cases of serotonin syndrome associated with agitation, confusion, rigidity, pyrexia and myoclonus have been reported by patients treated with antidepressants/SNRI concomitantly with rasagiline.
Reproterol, tricyclic antidepressant
The co-administration with tricyclic antidepressants may cause increased effect of reproterol on the cardiovascular system
Reserpine, tricyclic antidepressant
The combination may potentiate the effect of tricyclic antidepressant. The antidepressant may decrease/abolish the central hypotensive effect. Combination should be avoided
Rifampicin [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Rifampicin is a potent inducer of certain cytochrome P-450 enzymes. Coadministration of rifampicin with drugs that are also metabolised through these cytochrome P-450 enzymes may accelerate the metabolism and reduce the activity of these other drugs.
Rilmenidine, tricyclic antidepressant
The co-administration may partially abolish the hypotensive effect of rilmenidine
Risperidone [1], tetracyclic antidepressant ---> SmPC of [1] of eMC
Caution is advised when prescribing risperidone with medicinal products known to prolong the QT interval
Risperidone [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Caution is advised when prescribing risperidone with medicinal products known to prolong the QT interval
Ritonavir, tricyclic antidepressant
Ritonavir may increase the plasma levels of antidepressant
Roxithromycin, tricyclic antidepressant
Caution is warranted for concomitant use of roxitromycin with other QT interval prolonging medicines
Safinamide [1], tetracyclic antidepressant ---> SmPC of [1] of EMA
Serious adverse reactions have been reported with the concomitant use of tetracyclic antidepressants and MAO inhibitors
Safinamide [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Serious adverse reactions have been reported with the concomitant use of tricyclic antidepressants and MAO inhibitors
Salbutamol, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
The effects of salbutamol may be altered by tricyclic antidepressants
Salmeterol, tricyclic antidepressant
The tricyclic antidepressant may enhance the cardiovascular adverse effects of salmeterol
Saquinavir/ritonavir, tricyclic antidepressant ---> SmPC of [saquinavir] of EMA
The combination is contraindicated due to the potential for life threatening cardiac arrhythmia
Scopolamine, tetracyclic antidepressant
Scopolamine may enhance the anticholinergic effect
Scopolamine, tricyclic antidepressant
Scopolamine may enhance the anticholinergic effect
Sedative antidepressants, sufentanil
The co-administration may enhance the respiratory depressor effect of sufentanil
Sedative antidepressants, tiapride
Enhancement of CNS depressant effect
Sedative antidepressants, tramadol [2] ---> SmPC of [2] of eMC
Concomitant administration of tramadol with other centrally acting drugs may potentiate CNS depressant effects.
Seizure-threshold lowering drugs, tricyclic antidepressant
Caution is advised when concomitantly using medicinal products capable of lowering the seizure threshold
Selegiline [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Severe CNS toxicity has been reported in patients with the combination of tricyclic antidepressants and selegiline. The co-administration is contraindicated
Sertraline [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Clinical relevant interactions may occur with other CYP 2D6 substrates with a narrow therapeutic index, especially at higher sertraline dose levels.
Sodium oxybate [1], tricyclic antidepressant ---> SmPC of [1] of EMA
A possible additive effect of antidepressants and sodium oxybate cannot be excluded. The rate of adverse events has increased when sodium oxybate is co-administered with tricyclic antidepressants.
Sotalol, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Sotalol should be given with extreme caution in conjunction with other drugs known to prolong the QT-interval. Drugs that prolong the QT-interval may cause torsades de pointes. The co-administration with sotalol is contraindicated
SSRI, tricyclic antidepressant
Antidepressants with serotonergic effect can lower the seizure threshold. Caution is advised when concomitantly using other medicinal products capable of lowering the seizure threshold
Strong CYP2D6 inhibitors, tricyclic antidepressant
Strong CYP2D6 inhibitors should not be used concomitantly with tricyclic antidepressants
Sulpiride [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Combination of sulpiride with drugs which could induce torsades de pointes or prolong the QT interval is not recommended
Sumatriptan, tricyclic antidepressant
Potential risk of a serotoninergic syndrome. The concomitant use should be done with caution
Sympathomimetics, tetracyclic antidepressant
The antidepressant may enhance the cardiovascular effects of sympathomimetic agent resulting in severe arrhytmias, tachycardia, hypertension and hyperpyrexia
Sympathomimetics, tricyclic antidepressant
Hypertension and an increased risk of arrhythmias may occur if sympathomimetic agents are given to patients receiving tricyclic antidepressants.
Talinolol, tricyclic antidepressant
The co-administration may cause a pronounced hypotension
Telithromycin [1], tricyclic antidepressant ---> SmPC of [1] of EMA
Due to a potential to increase the QT interval, telithromycin should be used with care during concomitant administration with QT interval prolonging agents
Terbutaline, tricyclic antidepressant
The co-administration may enhance the effect of terbutaline on the cardiovascular system
Terfenadine, tricyclic antidepressant
The co-administration of terfenadine with potential arrhytmogenic medicinal products is contraindicated
Terlipressin, tricyclic antidepressant
Terlipressin can cause ventricular arrhythmias (incl. torsades de pointes). The combination with drugs that prolong the QT interval should be done with extreme caution
Tetracyclic antidepressant, trihexyphenidyl
Additive anticholinergic effect
Tetracyclic antidepressant, tropicamide
Enhancement of anticholinergic effect
Tetracyclic antidepressant, verapamil
The co-administration may enhance the hypotensive effect of verapamil
Tetracyclic antidepressant, xylometazoline [2] ---> SmPC of [2] of eMC
As for all sympathomimetics, a reinforcement of the systemic effects of xylometazoline by concomitant use of tetracyclic antidepressants cannot be excluded, especially in case of overdose.
Tetryzoline, tricyclic antidepressant
Concomitant use of tetryzoline with tricyclic antidepressants may enhance the vasoconstrictor effect and increase the blood pressure
Thiazides, tricyclic antidepressant
There is an increased risk of postural hypotension with tricyclic antidepressants.
Thiopental, tricyclic antidepressant
Increased risk of arrhythmias and hypotension when general anaesthetics given with tricyclic antidepressants.
Thioridazine, tricyclic antidepressant
The coadministration may increase the plasma levels of tricyclic antidepressants and/or phenothiazines. It has been reported that the co-administration may result in heart rhythm disorders
Thyroid hormones, tricyclic antidepressant ---> SmPC of [clomipramine] of eMC
Caution is indicated during concomitant treatment with thyroid preparations and tricyclic antidepressant, since aggravation of unwanted cardiac effects may occur.
Tiapride, tricyclic antidepressant
Tiapride should not be combined with drugs that prolong the QT interval. These drugs (with the exception of anti-infectious) should be discontinued, if possible, if they induce torsades de pointes
Timolol, tricyclic antidepressant [2] ---> SmPC of [2] of eMC
Concomitant administration of timolol with tricyclic antidepressants may increase the blood pressure lowering effect.
Tolbutamide, tricyclic antidepressant
Increased hypoglycaemic effects have occurred or might be expected
Tramadol [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Tramadol can induce convulsions and increase the potential of other seizure threshold-lowering medicinal products to cause convulsions. Concomitant therapeutic use of tramadol and serotonergic drugs may cause serotonin toxicity.
Tramazoline, tricyclic antidepressant
Concomitant use of tramazoline and tricyclic antidepressants may increase the blood pressure. Concomitant use should be avoided
Trandolapril [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Combination of trandolapril with tricyclic antidepressant increases the risk of orthostatic hypotension.
Tranylcypromine, tricyclic antidepressant
The co-administration is contraindicated. Possible serotoninergic syndrome with severe symptoms.
Trazodone [1], tricyclic antidepressant ---> SmPC of [1] of eMC
Interactions in terms of serotonine syndrome/malignant neuroleptic syndrome have been described in case of concomitant use of trazodone and other serotonergically acting substances
Triamterene/hydrochlorothiazide, tricyclic antidepressant
The antihypertensive effect of triamterene/hydrochlorothiazide may be enhanced by tricyclic antidepressants
Tricyclic antidepressant, trihexyphenidyl
Synergy has been reported between trihexyphenidyl and tricyclic antidepressants, probably because of an additive effect at the receptor site.
Tricyclic antidepressant, triptans
Potential risk of a serotoninergic syndrome. The concomitant use should be done with caution
Tricyclic antidepressant, tropicamide
Enhancement of anticholinergic effect
Tricyclic antidepressant, trospium [2] ---> SmPC of [2] of eMC
Potentiation of the effect of drugs with anticholinergic action
Tricyclic antidepressant, tryptophan
Tryptophane may enhance the effect of the tricyclic antidepressant
Tricyclic antidepressant, urinary alkalinizing agents
The urinary alkalinizing agent, increases the pH of renal tubular urine and decreases the urinary excretion of tricyclic antidepressant
Tricyclic antidepressant, valsartan
The combination may increase the antihypertensive effect
Tricyclic antidepressant, verapamil
The co-administration may enhance the hypotensive effect of verapamil
Tricyclic antidepressant, vortioxetine [2] ---> SmPC of [2] of EMA
Antidepressants with serotonergic effect can lower the seizure threshold. Caution is advised when concomitantly using other medicinal products capable of lowering the seizure threshold
Tricyclic antidepressant, xipamide [2] ---> SmPC of [2] of eMC
The dosage of other hypotensive drugs may require adjustment when used in conjunction with xipamide
Tricyclic antidepressant, xylometazoline [2] ---> SmPC of [2] of eMC
As for all sympathomimetics, a reinforcement of the systemic effects of xylometazoline by concomitant use of tricyclic antidepressants cannot be excluded, especially in case of overdose.
Tricyclic antidepressant, yohimbine
The co-administration may potentiate the effect and adverse reactions of tricyclic antidepressant
Tricyclic antidepressant, zofenopril
Postural hypotension may occur
Tricyclic antidepressant, zotepine
The co-administration may increase the plasma levels of both active principles
Tricyclic antidepressant, zuclopenthixol [2] ---> SmPC of [2] of eMC
The metabolism of tricyclic antidepressants may be inhibited